Filing Flows › Beta Bionics (BBNX) › Q3 2026 › vs Q2 2026
Beta Bionics (BBNX) Q3 2026 vs Q2 2026 (quarter over quarter)
Beta Bionics's revenue rose $3.5M (+11%) from $32.0M in Q2 2026 to $35.5M in Q3 2026.
Beta Bionics, Q3 2026: revenue $35.5M (+30% year over year), operating margin -74.9%, net loss $24.4M, operating cash flow −$12.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $35.5M | $32.0M | $3.5M | +11% |
| Other income, net | $2.3M | $2.2M | $81K | +4% |
| Net loss | $24.4M | $23.4M | $950K | +4% |
| Costs & expenses | $62.1M | $57.6M | $4.5M | +8% |
| Operating costs | $62.1M | $57.6M | $4.5M | +8% |
| Cost of revenue | $15.2M | $13.1M | $2.1M | +16% |
| Research & development | $12.0M | $10.2M | $1.7M | +17% |
| Sales & marketing | $25.1M | $24.6M | $484K | +2% |
| General & admin | $9.8M | $9.6M | $241K | +3% |
| Operating cash sources | $24.4M | $23.4M | $950K | +4% |
| Depreciation | $892K | $709K | $183K | +26% |
| Share-based compensation | $6.7M | $7.0M | −$301K | -4% |
| Working capital & other | $4.5M | $1.1M | $3.4M | +322% |
| Cash used in operations | $12.3M | $14.6M | −$2.3M | -16% |
| Net loss absorbed | $24.4M | $23.4M | $950K | +4% |
Questions
How much did Beta Bionics's revenue grow quarter over quarter in Q3 2026?
Beta Bionics's revenue rose $3.5M (+11%) from $32.0M in Q2 2026 to $35.5M in Q3 2026.